B Cell Protein Proves Out as Novel Myeloma Target

]]>(MedPage Today) -- Belantamab mafodotin, a biologic agent targeting the B-cell maturation antigen (BCMA), elicited responses in about one-third of patients with relapsed or refractory multiple myeloma in the phase II DREAMM-2 study.In this difficult...